In recent years, the small molecule inhibitor GANT-61 is the most widely appreciated drug target of the GLI1/2, with improved potency and chemical stability, has strong and extensive anti-tumor effects in pancreatic cancer, breast cancer, rhabdomyosarcoma, glioblastoma, myeloid leukemia, osteosarcoma, melanomas, and so on [23, 24]. Here, GLI1 is linked to breast carcinoma.